Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 7/20 | 0.66 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5396948 | 0.92 | METAP2 (0.55) | METAP2SMN1; SMN2KDM1AGAAHSD17B10 | |
| SCHEMBL5373695 | 0.91 | METAP2 (0.54) | METAP2SLC2A1SMN1; SMN2KDM1AGAA | |
| SCHEMBL5381685 | 0.89 | METAP2 (0.52) | METAP2SMN1; SMN2KDM1AGAAHSD17B10 | |
| SCHEMBL5372346 | 0.88 | METAP2 (0.53) | METAP2SLC2A1SMN1; SMN2KDM1AGAA | |
| SCHEMBL5387236 | 0.88 | METAP2 (0.62) | METAP2SMN1; SMN2GAANPSR1ALDH1A1 | |
| SCHEMBL5381797 | 0.86 | METAP2 (0.49) | METAP2SLC2A1SMN1; SMN2KDM1AGAA | |
| SCHEMBL5392093 | 0.86 | METAP2 (0.49) | METAP2SMN1; SMN2KDM1AGAAHSD17B10 | |
| SCHEMBL5382602 | 0.84 | METAP2 (0.54) | METAP2SMN1; SMN2KDM1AGAAHSD17B10 | |
| SCHEMBL5372033 | 0.84 | METAP2 (0.65) | METAP2SMN1; SMN2HSD17B10NPSR1ALDH1A1 | |
| SCHEMBL5382003 | 0.84 | METAP2 (0.52) | METAP2SMN1; SMN2KDM1AGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304082-B2 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | METAP2, METAP1, DNPEP | METAP2 1/4885SLC2A1 1376/4885SMN1; SMN2 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.